Clinical trials

Primary Investigator in Clinical Trials

CA073-1003 : A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma
A Study of Bleximenib in Combination with VEN+AZA for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations who are ineligible for intensive chemotherapy clinical study
A Phase 1b/2a, Open-Label, Sequential-Cohort, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Effectiveness of Budoprutug (TNT119) in Subjects with Immune Thrombocytopenia (ITP)
KRT-232-115 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) That Have a Suboptimal Response to Ruxolitinib, Sponsor: Kartos Therapeutics, Inc.
XPORT-MF-044 A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia, Sponsor Kariopharm Therapeutics Inc
EpcoReal: Μια πολυεθνική, προοπτική μελέτη παρατήρησης του epcoritamab στο Μη Hodgkin Λέμφωμα (NHL) που περιλαμβάνει δύο κοόρτεις ασθενών [ασθενείς με (διάχυτο) λέμφωμα από μεγάλα Β-κύτταρα που λαμβάνουν θεραπεία 2ης ή/και μεταγενέστερης γραμμής (3L+ [D]LBCL) και ασθενείς με οζώδες λέμφωμα που λαμβάνουν θεραπεία 2ης ή/και μεταγενέστερης γραμμής (3L+ FL)
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating with Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)
A Phase 2 study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor, EAE-115, Sponsor Hellenic Society of Haematology
A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide, and Dexamethasone, followed by Isatuximab and Lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment, EAE-116, Sponsor Hellenic Society of Haematology
An open-label, 3-arm, multicenter, randomized phase 3 study to evaluate the efficacy and safety of Elranatamab (pf-06863135) monotherapy and Elranatamab + Daratumumab versus Daratumumab + Pomalidomide + Dexamethasone in participants with Relapsed/Refractory Multiple Myeloma who have received at least 1 prior line of therapy including Lenalidomide and a proteasome inhibitor, MagnetisMM 05 / C1071005, Sponsor Pfizer
An open-label, 2-arm, multicenter, randomized phase 3 study to evaluate the efficacy and safety of elranatamab (pf-06863135) + daratumumab + lenalidomide versus daratumumab + lenalidomide + dexamethasone in transplant-ineligible participants with newly-diagnosed multiple myeloma, C1071006, MagnetisMM-6, Sponsor Amgen
A randomized, 2-arm, phase 3 study of Elranatamab (PF-06863135) versus Lenalidomide in patients with newly diagnosed Multiple Myeloma who are minimal residual disease-positive after undergoing autologous stem-cell transplantation, MagnetisMM 07 / C1071007, Sponsor Pfizer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Following a Suboptimal Response to Ruxolitinib” (BOREAS-2)
A phase 1/3 study to evaluate the efficacy and safety of selinexor, a selective inhibitor of nuclear export, in combination with ruxolitinib in treatment-naïve patients with myelofibrosis, XPORT-MF-034, Sponsor Karyopharm
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment, Sponsor Kartos Therapeuticals
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (CPI 0610-04, MANIFEST-2)
Double-Blind, Randomized, Placebo-Controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia, Sponsor Octapharma
Real-world evidence of the use of a carfilzomib triplet including an anti-CD38 antibody in patients with multiple myeloma who have received at least one prior therapy, Sponsor Amgen
Πρότυπα Θεραπείας σε Πραγματικές Συνθήκες και Κλινικές Εκβάσεις σε Μη Κατάλληλους Ασθενείς με ΟΜΛ στην Ελλάδα οι οποίοι Λαμβάνουν Πρώτης Γραμμής Συστηματική Θεραπεία ή την Καλύτερη Υποστηρικτική Φροντίδα», Μελέτη SECURE, Sponsor: AbbVie
A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Combination with Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma who are BTK inhibitor-naïve, Sponsor: Janssen Pharmaceuticals
A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed with Myelofibrosis through Chart Review, the METER study, Sponsor Abbvie
Προοπτική μη παρεμβατική μελέτη για την περιγραφή της αποτελεσματικότητας και της ασφάλειας του ως θεραπεία πρώτης γραμμής σε ασθενείς με οξεία μυελοειδή λευχαιμία (ΟΜΛ) οι οποίοι δεν είναι κατάλληλοι για εντατική χημειοθεραπεία στη συνήθη κλινική πρακτική στην Ελλάδα», Μελέτη SURVIVE, Sponsor: AbbVie
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator’s Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Μια πολυκεντρική, ανοιχτής ετικέτας, τυχαιοποιημένη μελέτη Φάσης III για την αξιολόγηση της αποτελεσματικότητας και της ασφάλειας του Belantamab Mafodotin σε συνδυασμό με πομαλιδομίδη και δεξαμεθαζόνη (B-Pd) έναντι του συνδυασμού με πομαλιδομίδη, βορτεζομίμπη και δεξαμεθαζόνη (PVd) σε συμμετέχοντες με υποτροπιάζον/ανθεκτικό πολλαπλό μυέλωμα (DREAMM 8), Sponsor GlaxoSmithKline
An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of MM with Carfilzomib, Pomalidomide, and Dexamethasone (KPd), Sponsor Amgen
Μελέτη MiraCLLe: Μια Eπιδημιολογική, Προοπτική μελέτη κοόρτης, διετούς διάρκειας για να Καταγράψει την Πραγματική Στρατηγική Αντιμετώπισης Πρώτης και Δεύτερης Γραμμής θεραπεία, στην Καθ’ Ημέρα Κλινική Πράξη, Αποτελέσματα Θεραπείας, Ποιότητα Ζωής και Χρήση Πόρων σε Ασθενείς με Χρόνια Λεμφοκυτταρική Λευχαιμία στην Ελλάδα, Sponsor Astra Zeneca
A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of IMP in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP), Sponsor: UCB Biopharma SRL
Study M20-638: A Phase 3, Multicenter, Randomized, Open-Label Trial of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to Rituximab and Lenalidomide (R2) alone in Subjects with Relapsed or Refractory Follicular Lymphoma, Sponsor: AbbVie
Study M20-621: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma Version Number: 1.0, Sponsor: AbbVie
PCYC-1143-CA: Μελέτη Φάσης 3 για την ιμπρουτινίμπη σε συνδυασμό με τη βενετοκλάξη σε ασθενείς μελέμφωμα από κύτταρα του μανδύα, A Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma, Sponsor: Pharmacyclics
P19-568/Concrete: Κλινικές Εκβάσεις ασθενών με υποτροπιάζουσα/ανθεκτική Χρόνια ΛεμφοκυτταρικήΛευχαιμία (Υ/Α ΧΛΛ) οι οποίοι υποβάλλονται σε θεραπεία με Venetoclax σε συνθήκες καθημερινής κλινικήςπρακτικής στην Ελλάδα, (Clinical outcomes of relapse/refractory Chronic Lymphocytic Leukemia (R/R CLL) patients treated with venetoclax in routine clinical settings in Greece) Sponsor: AbbVie Φαρμακευτική ΑΕ
ΑSPER-III-19-1: Μία φάσης 3, διπλή-τυφλή, πολυκεντρική, τυχαιοποιημένη, ελεγχόμενη με εικονικόφάρμακο μελέτη για την αξιολόγηση της αποτελεσματικότητας, της ασφάλειας και της ανεκτικότητας τηςεισπνεόμενης Ιτρακοναζόλης σε μορφή ξηράς κόνεως για την πρόληψη της διηθητικήςμυκητιασικής λοίμωξης σε ασθενείς με Οξεία Λευχαιμία και Ουδετεροπενία, (A phase 3, double-blind, multicentric, randomized, placebo-controlled study to assess the efficacy, safety and tolerability of Itraconazole dry powder for inhalation for the prevention of invasive mould disease in patients with Acute Leukaemia and Neutropaenia) Sponsor: Laboratoires SMB S.A
Αναδρομική ανάλυση κλινικών εκβάσεων ασθενών με υποτροπιάζουσα/ανθεκτική Χρόνια Λεμφοκυτταρική Λευχαιμία (Υ/Α ΧΛΛ) που υποβλήθηκαν σε θεραπεία με venetoclax: Αναδρομική ανάλυση από την Ελλάδα, Sponsor: AbbVie Φαρμακευτική ΑΕ
Α phase III, randomized, openlabel, active-controlled, multicenter study evaluating the efficacy and safety of Crovalimab versus Eculizumab in adult and adolescent patients with paroxysmal nocturnal hemoglobinuria not previously treated with complement inhibitors, Sponsor Hoffmann-La Roche
An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd), Sponsor: Amgen
Τυχαιοποιημένη, διπλά-τυφλή, ελεγχόμενη με εικονικό φάρμακο πολυκεντρική μελέτη φάσης ΙΙΙ της αζακιτιδίνης με ή χωρίς MBG453 για τη θεραπεία ασθενών με ενδιάμεσου, υψηλού ή πολύ υψηλού κινδύνου μυελοδυσπλαστικό σύνδρομο (ΜΔΣ) σύμφωνα με τα κριτήρια IPSS-R, ή με χρόνια μυελομονοκυτταρική λευχαιμία-2 (CMML-2), Sponsor: Novartis

Clinical Trials open for enrollment

Clinical_Trials_Register_v4___Google_Sheets-ready

Understanding Clinical Trials: A Patient & Family Guide

Discover what clinical trials are, how they work, and what to consider before joining one, especially in hematology.

🧭 Why This Guide Matters

If you or someone you love is facing a serious condition, your doctor may recommend considering a clinical trial. But what exactly does that mean? How do these trials work and what are the risks and benefits?

This guide aims to help patients and families understand clinical trials, especially in the field of hematology. Empowered decisions start with clear, compassionate information.

1. 🔬 What Are Clinical Trials?

Clinical trials are research studies involving real people. They test whether new treatments, such as medications, therapies, or diagnostic tools, are safe and effective.

They are how medicine moves forward. Many of the treatments we use today began as clinical trials.

Why Are They Important?

They improve care for future patients
They help researchers understand diseases
They offer access to new treatments before they are widely available

2. 🧭 How Do Clinical Trials Work?

Most clinical trials follow four key phases:

Phase What It Tests

Phase 1 Is it safe? What’s the best dose?

Phase 2 Does it work? Are there side effects?

Phase 3 Is it better than current treatments?

Phase 4 How does it perform long-term, after approval?

Trial Types

Randomized trials: Participants are randomly assigned to treatment groups
Controlled trials: Compare new treatments with standard care
Observational studies: Monitor outcomes without assigning treatments

3. 🌱 Benefits of Joining a Trial

Joining a clinical trial is a personal decision—but it can come with meaningful benefits:

Access to new treatments
Closer medical monitoring
Contribution to science and future patients
Financial support (sometimes)

4. ⚠️ What Are the Risks?

No treatment is risk-free—and clinical trials are no exception.

Side effects or reactions may occur
The treatment might not help your condition
Extra appointments or tests may be needed

However, your rights as a participant are protected.

5. 🧾 Your Rights as a Participant

You have the right to:

Be fully informed before you join
Ask any question, at any time
Leave the trial whenever you choose

Every clinical trial must follow strict ethical standards, including informed consent.

6. 🧩 Who Can Join?

Each trial has specific eligibility criteria, including:

Age or gender
Type and stage of disease
Previous treatments

7. 🔎 How to Find a Clinical Trial

Finding the right trial can feel overwhelming. Here’s where to begin:

Ask your healthcare team
Search online: ClinicalTrials.gov
Contact patient advocacy groups

For hematology-specific trials, your local university hospital or hematology department may be the best starting point.

8. 🧳 Getting Ready to Join

Before joining a clinical trial:

Gather your medical history
Prepare a list of medications and allergies
Bring questions to your meeting
Ask about time commitment, location, and tests involved

Being prepared helps you and your care team make the best decision—together.

💬 Final Thoughts

Clinical trials are the backbone of medical progress. They help us discover better treatments, safer therapies, and ultimately, more hope for the future.

Joining a trial is a courageous decision. If you’re considering it, take time to understand the process, your rights, and your options. You are never alone in this journey.

Download the guide

Knowledge becomes meaningful when it returns to people

Page updated

Report abuse